Pharmacokinetics Services Market Size, Share & Trends Analysis Report By Drug Type (Small Molecules, Large Molecules (Biopharmaceuticals)), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025

Published: May, 2018 | Pages: 100 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

The global pharmacokinetics services market size is expected to reach USD 1.2 billion by 2025, according to a new report by Grand View Research, Inc., registering an 8.3% CAGR during the forecast period. Rising adoption of pharmacokinetic and toxicology studies for determination of several parameters such as no-observed-effect levels (NOEL), human equivalent doses (HED) levels, and pharmacokinetic/pharmacodynamic (PK/PD) drivers are expected to fuel market growth. 

Thorough understanding of the pharmacokinetic profile of a potential drug candidate plays a major role in the success of a drug discovery program. In addition to this, regulatory bodies have played a major role in the progress of this market through establishing defined guidelines for conducting PK studies. There are a substantial number of CROs engaged in conducting PK studies in accordance with relevant EMEA, ICH, FDA, GCP, and other regulatory guidelines.

Growing concern for effective implementation of PK services in the drug development process is anticipated to drive investments in this sector. Several conferences and certification courses are being conducted across the world to increase the understanding of various paradigms associated with pharmacokinetics application in clinical and preclinical drug development.

Further key findings from the report suggest:

• Based on drug type, PK services for small molecules dominated the market in 2017 and is expected to maintain its lead during the forecast period fueled by high service penetration and growing popularity of generics

• PK services for large molecules are expected to grow significantly during the forecast period, driven by presence of significant number of biologics and biosimilars in the clinical development phase

• Presence of a large number of biopharmaceutical and pharmaceutical manufacturing entities in U.S. has resulted in North America accounting for the largest share in 2017

• Asia Pacific is expected to grow lucratively throughout the forecast period thanks to constant economic growth in several countries, which has attracted significant attention from global CROs and resulted in business expansions

• Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; and Eurofins Scientific, Inc. are some of the key service providers

• These CROs are undertaking various initiatives in order to capitalize on new market avenues and enhance their share in the future market.

 Table of Contents

Chapter 1 Executive Summary
                  1.1 Market Snapshot

Chapter 2 Research Methodology
                  2.1 Information procurement
                  2.2 Data Analysis

Chapter 3 Pharmacokinetics Services Market Variables, Trends & Scope
                  3.1 Market Segmentation & Scope
                      3.1.1 Market driver analysis
                          3.1.1.1 Focused efforts to establish a standardized pharmacokinetic monitoring approach
                          3.1.1.2 Robust drug pipeline and ongoing clinical studies
                          3.1.1.3 Conferences that aimed at growing awareness about the role of pharmacokinetics
                      3.1.2 Market restraint analysis
                          3.1.2.1 Limitations associated with in vitro PKPD studies
                  3.2 Penetration & Growth Prospect Mapping For Drug Type, 2017
                  3.3 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
                  3.4 Industry Analysis - Porter's

Chapter 4 Pharmacokinetics Services Market: Drug Type Estimates & Trend Analysis
                  4.1 Pharmacokinetics Services Market: Drug Type Movement Analysis
                  4.2 Small Molecule Pharmacokinetics Services
                      4.2.1 Small molecule pharmacokinetic services market, 2013 - 2025 (USD Million)
                  4.3 Large Molecule Pharmacokinetic Services
                      4.3.1 Large molecule pharmacokinetic services market, 2013 - 2025 (USD Million)

Chapter 5 Pharmacokinetics Services Market: Regional Estimates & Trend Analysis, by Drug Type
                  5.1 Pharmacokinetics Services Market Share By Region, 2016 & 2025
                  5.2 North America
                      5.2.1 North America pharmacokinetics services market, 2013 - 2025 (USD Million)
                      5.2.2 U.S.
                          5.2.2.1 U.S. pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                      5.2.3 Canada
                          5.2.3.1 Canada pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                  5.3 Europe
                      5.3.1 Europe pharmacokinetics services market, 2013 - 2025 (USD Million)
                      5.3.2 Germany
                          5.3.2.1 Germany pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                      5.3.3 U.K.
                          5.3.3.1 U.K. pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                  5.4 Asia Pacific
                      5.4.1 Asia Pacific pharmacokinetics services market, 2013 - 2025 (USD Million)
                      5.4.2 China
                          5.4.2.1 China pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                      5.4.3 India
                          5.4.3.1 India pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                      5.4.4 Japan
                          5.4.4.1 Japan pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                  5.5 Latin America
                      5.5.1 Latin America pharmacokinetics services market, 2013 - 2025 (USD Million)
                      5.5.2 Brazil
                          5.5.2.1 Brazil pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
                  5.6 Middle East and Africa
                      5.6.1 MEA pharmacokinetics services market, 2013 - 2025 (USD Million)
                      5.6.2 South Africa
                          5.6.2.1 South Africa pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)

Chapter 6 Competitive Landscape
                  6.1 Strategy Framework
                  6.2 Market Participation Categorization
                  6.3 Company Profiles
                      6.3.1 Evotec AG
                          6.3.1.1 Company overview
                          6.3.1.2 Cyprotex Limited
                              6.3.1.2.1 Company overview
                          6.3.1.3 Financial performance
                              6.3.1.3.1 Financial performance
                          6.3.1.4 Product benchmarking
                          6.3.1.5 Strategic initiatives
                      6.3.2 Certara, L.P.
                          6.3.2.1 Company overview
                          6.3.2.2 Financial performance
                          6.3.2.3 Product benchmarking
                          6.3.2.4 Strategic initiatives
                      6.3.3 Pacific BioLabs
                          6.3.3.1 Company overview
                          6.3.3.2 Financial performance
                          6.3.3.3 Product benchmarking
                          6.3.3.4 Strategic initiatives
                      6.3.4 GVK Biosciences Private Limited
                          6.3.4.1 Company overview
                          6.3.4.2 Financial performance
                          6.3.4.3 Product benchmarking
                          6.3.4.4 Strategic initiatives
                      6.3.5 Shanghai Medicilon Inc.
                          6.3.5.1 Company overview
                          6.3.5.2 Financial performance
                          6.3.5.3 Product benchmarking
                          6.3.5.4 Strategic initiatives
                      6.3.6 Pharmaceutical Product Development, LLC
                          6.3.6.1 Company overview
                          6.3.6.2 Financial performance
                          6.3.6.3 Product benchmarking
                          6.3.6.4 Strategic initiatives
                      6.3.7 Charles River Laboratories International, Inc.
                          6.3.7.1 Company overview
                          6.3.7.2 Financial performance
                          6.3.7.3 Product benchmarking
                          6.3.7.4 Strategic initiatives
                      6.3.8 PAREXEL International Corporation
                          6.3.8.1 Company overview
                          6.3.8.2 Financial performance
                          6.3.8.3 Product benchmarking
                          6.3.8.4 Strategic initiatives
                      6.3.9 Eurofins Scientific, Inc.
                          6.3.9.1 Company overview
                          6.3.9.2 Financial performance
                          6.3.9.3 Product benchmarking
                          6.3.9.4 Strategic initiatives
                      6.3.10 Frontage Labs
                          6.3.10.1 Company overview
                          6.3.10.2 Concord
                              6.3.10.2.1 Company overview
                          6.3.10.3 Financial performance
                          6.3.10.4 Product benchmarking
                          6.3.10.5 Strategic initiatives
                      6.3.11 SGS SA
                          6.3.11.1 Company overview
                          6.3.11.2 Financial performance
                          6.3.11.3 Product benchmarking
                          6.3.11.4 Strategic initiatives
                      6.3.12 LGC Limited
                          6.3.12.1 Company overview
                          6.3.12.2 Financial performance
                          6.3.12.3 Product benchmarking
                          6.3.12.4 Strategic initiatives
                      6.3.13 Creative Bioarray
                          6.3.13.1 Company overview
                          6.3.13.2 Financial performance
                          6.3.13.3 Product benchmarking
                          6.3.13.4 Strategic initiatives

List of Tables

TABLE 1 Top new drugs in the pipeline for 2018
TABLE 2 North America pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 3 U.S. pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 4 Canada pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 5 Europe pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 6 Germany pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 7 U.K. pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 8 Asia Pacific pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 9 China pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 10 India pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 11 Japan pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 12 Latin America pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 13 Brazil pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 14 MEA pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)
TABLE 15 South Africa pharmacokinetics services market, by drug type, 2013 - 2025 (USD Million)

List of Figures

FIG. 1 Market summary
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Various multidisciplinary drug development functions that interfaces pharmacokinetics
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 Penetration & growth prospect mapping for Application, 2017
FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 15 Porter's Five Forces Analysis
FIG. 16 Pharmacokinetics services market: Drug type outlook key takeaways
FIG. 17 Pharmacokinetics services market: Drug type market movement analysis
FIG. 18 Global small molecule pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 19 Global large molecule pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 20 Regional market place: Key takeaways
FIG. 21 Pharmacokinetics market by region: Regional movement analysis
FIG. 22 North America pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 23 U.S. pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 24 Canada pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 25 Europe pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 26 Germany pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 27 U.K. pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 28 Asia Pacific pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 29 Breakdown of Chinese CRO industry
FIG. 30 China pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 31 India pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 32 Japan pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 33 Latin America pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 34 Brazil pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 35 MEA pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 36 South Africa pharmacokinetic services market, 2013 - 2025 (USD Million)
FIG. 37 Strategy framework
FIG. 38 Participant categorization